Holen Sie sich die Stockscreener-App
4.2799
0.23%
-0.0201
Vir Biotechnology Inc Aktie (VIR) Neueste Nachrichten
Vir Biotechnology, Inc. (NASDAQ:VIR) Analysts Are Cutting Their Estimates: Here's What You Need To Know - simplywall.st
A Quick Look at Today's Ratings for Vir Biotechnology(VIR.US), With a Forecast Between $12 to $31 - 富途牛牛
Vir Biotechnology, Inc. (NASDAQ:VIR) Q2 2025 Earnings Call Transcript - Insider Monkey
Vir Biotechnology’s Earnings Call Highlights Progress and Challenges - TipRanks
Vir Biotechnology (VIR.O) Plunges 14.5%: What’s Driving the Intraday Swoon? - AInvest
Vir Biotechnology's 12.4% Intraday Drop: A Technical and Order-Flow Deep Dive - AInvest
Earnings call transcript: Vir Biotech Q2 2025 results fall short, stock dips - Investing.com
Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta - BioSpace
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results - BioSpace
Vir Biotechnology outlines global patient recruitment and cash runway through mid-2027 amid hepatitis delta pipeline momentum - MSN
Vir Biotechnology 2025 Q2 Earnings Losses Narrow 19.8% as Net Income Declines - AInvest
Vir (VIR) Q2 Revenue Drops 61% - The Motley Fool
Vir Biotechnology Reports Q2 2025 Financial Results - TipRanks
Vir Biotechnology's Q2 2025 Performance and Future Outlook: A Contrarian's Playbook for a Biotech Underdog - AInvest
Vir Biotechnology: A High-Conviction Play in Hepatitis Delta and Next-Gen Oncology Innovation - AInvest
Transcript : Vir Biotechnology, Inc., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates - sharewise.com
Vir Biotechnology Q2 Earnings Fall Short of Estimates, Revenue Lags Behind - AInvest
Vir Biotechnology Q2 2025 Earnings Call Transcript - MarketBeat
Vir Biotechnology, Inc. SEC 10-Q Report - TradingView
Earnings Flash: (VIR) Vir Biotechnology Q2 Loss $0.80 Vs. FactSet Est. $0.72 Loss - MarketScreener
Vir Biotechnology Q2 revenue misses expectations, net loss narrows - MarketScreener
Vir Biotechnology reports Q2 EPS (80c), consensus (72c) - TipRanks
Vir Biotechnology Inc. (VIR) Misses Q2 EPS by 10c, provides guidance - StreetInsider
Press Release: Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results - 富途牛牛
Vir Biotechnology enrolls first participant in ECLIPSE 3 trial - TipRanks
Vir Biotechnology successfully initiates all trials in Eclipse registrational program - MarketScreener
Vir Biotechnology completes initiation of hepatitis delta program By Investing.com - Investing.com Nigeria
Vir Biotechnology enrolls first patient in ECLIPSE 3 hepatitis delta trial - StreetInsider
Vir Biotechnology Director SATO VICKI L Sells 22000 Shares at $4.99/Share. - AInvest
How strong is Vir Biotechnology Inc. company’s balance sheetAchieve breakthrough results with expert guidance - Jammu Links News
Is Vir Biotechnology Inc. a good long term investmentMaximize gains with data-driven stock picks - Jammu Links News
Vir Biotechnology initiates second pivotal trial in its global ECLIPSE registrational program for chronic hepatitis delta - European AIDS Treatment Group
Is Vir Biotechnology Inc. stock overvalued or undervaluedMaximize your returns with expert insights - Jammu Links News
What analysts say about Vir Biotechnology Inc. stockMassive stock growth - Jammu Links News
How does Vir Biotechnology Inc. generate profit in a changing economyConsistent double returns - Jammu Links News
Should I hold or sell Vir Biotechnology Inc. stock in 2025Discover high-impact stocks for your portfolio - Jammu Links News
Vir Biotechnology Inc. Stock Analysis and ForecastCapitalize on market trends with confidence - Jammu Links News
What are the latest earnings results for Vir Biotechnology Inc.Unlock exclusive stock market forecasts - Jammu Links News
What are Vir Biotechnology Inc. company’s key revenue driversUnmatched market performance - Jammu Links News
How many analysts rate Vir Biotechnology Inc. as a “Buy”Consistent triple returns - Jammu Links News
Published on: 2025-08-03 07:23:25 - Jammu Links News
When is Vir Biotechnology Inc. stock expected to show significant growthBuild a winning investment portfolio - Jammu Links News
Why is Vir Biotechnology Inc. stock attracting strong analyst attentionExceptional return forecasts - Jammu Links News
What are analysts’ price targets for Vir Biotechnology Inc. in the next 12 monthsUnlock powerful portfolio optimization tools - Jammu Links News
How does Vir Biotechnology Inc. compare to its industry peersBreakout Stocks Tracker For Consistent Profits - jammulinksnews.com
Vir Biotechnology Inc. Recovery Gathers Momentum on Chart SignalsLow Risk Equity Screener With Results Shared - metal.it
Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta - BioSpace
Vir Biotechnology shares rise 1.38% after-hours after initiating second pivotal trial in global ECLIPSE program for chronic hepatitis delta. - AInvest
Vir Biotech enrolls first patient in hepatitis delta virus trial - Investing.com Australia
Vir Biotechnology enrolls first patient in ECLIPSE 2 hepatitis delta trial - StreetInsider
0.46%
0.18%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):